Gareth P. Gregory

246 Clayton Rd
Clayton, VIC 3168, Australia

Last Updated: 09/26/2026

Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 74 publications

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.

Marked variation in eligibility criteria across registrational trials for relapsed diffuse large B-cell lymphoma limits applicability to clinical practice.

Journal: British journal of haematology
Published: March 11, 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances
Published: January 16, 2026

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Glofitamab plus gemcitabine and oxaliplatin for relapsed/refractory DLBCL: 3-year follow-up of STARGLO.

Journal: Blood advances
Published: January 16, 2026

End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.

End-of-treatment positron emission tomography/computed tomography complete remission is highly prognostic in nodal peripheral T-cell lymphoma: An Australasian-Canadian collaborative study.

Journal: British journal of haematology
Published: December 29, 2025

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.

Favezelimab plus pembrolizumab for anti-PD-1-refractory classic Hodgkin lymphoma: an open-label phase 1/2 study.

Journal: Blood neoplasia
Published: September 26, 2025

Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury.

Concomitant IV vancomycin causing delayed high-dose methotrexate clearance and acute kidney injury.

Journal: The Journal of antimicrobial chemotherapy
Published: August 12, 2025

Glofitamab with GemOx for diffuse large B-cell lymphoma - Authors' reply.

Glofitamab with GemOx for diffuse large B-cell lymphoma - Authors' reply.

Journal: Lancet (London, England)
Published: July 09, 2025

Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.

Refinement of primary central nervous system lymphoma prognostication and response assessment using 3-dimensional MRI.

Journal: Neuro-oncology advances
Published: June 27, 2025

Burkitt lymphoma: click here to add to CAR-T?

Burkitt lymphoma: click here to add to CAR-T?

Journal: Blood
Published: June 05, 2025

Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.

Prognostic value of tumor bulk in modern management of common lymphoma subtypes: an Australasian Lymphoma and Related Diseases Registry study.

Journal: Haematologica
Published: March 28, 2025

Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at Relapse.

Dynamic Profiling of Cell Free Tumour DNA in Aggressive B-Cell Lymphoma From Diagnosis to Transformation at Relapse.

Journal: EJHaem
Published: March 24, 2025

Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.

Meeting trial eligibility in Follicular lymphoma patients is associated with overall survival but not progression-free survival.

Journal: Journal of the National Cancer Institute
Published: January 07, 2025
Showing 1-12 of 74

Last Updated: 09/26/2026